{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:38Z","timestamp":1787062718549,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). Despite being more effective than monotherapies, they produce frequent adverse drug reactions (ADRs). Institutions such as Food and Drug Administration and European Medicines Agency recommend precaution with\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    poor metabolizers (PMs) that receive\n                    <jats:italic>CYP3A4<\/jats:italic>\n                    inhibitors and tamsulosin. However, no specific pharmacogenetic guideline exists for tamsulosin. Furthermore, to date, no pharmacogenetic information is available for dutasteride. Henceforth, we studied the pharmacokinetics and safety of dutasteride\/tamsulosin 0.5\u00a0mg\/0.4\u00a0mg capsules according to 76 polymorphisms in 17 candidate pharmacogenes. The study population comprised 79 healthy male volunteers enrolled in three bioequivalence, phase-I, crossover, open, randomized clinical trials with different study designs: the first was single dose in fed state, the second was a single dose in fasting state, and the third was a multiple dose. As key findings,\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    PMs (i.e., *4\/*4 and *4\/*5 subjects) and intermediate metabolizers (IMs) (i.e., *1\/*4, *1\/*5, *4\/*15 individuals) presented higher AUC (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004), higher t\n                    <jats:sub>1\/2<\/jats:sub>\n                    (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.008), and lower Cl\/F (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.006) when compared with NMs (*1\/*1 individuals) and UMs (1\/*1 \u00d7 2 individuals) after multiple testing correction. Moreover, fed volunteers showed significantly higher t\n                    <jats:sub>max<\/jats:sub>\n                    than fasting individuals. Nominally significant associations were observed between dutasteride exposure and\n                    <jats:italic>CYP3A4<\/jats:italic>\n                    and\n                    <jats:italic>CYP3A5<\/jats:italic>\n                    genotype and between tamsulosin and\n                    <jats:italic>ABCG2<\/jats:italic>\n                    ,\n                    <jats:italic>CYP3A5<\/jats:italic>\n                    , and\n                    <jats:italic>SLC22A1<\/jats:italic>\n                    genotypes. No association between the occurrence of adverse drug reactions and genotype was observed. Nonetheless, higher incidence of adverse events was found in a multiple-dose clinical trial. Based on our results, we suggest that dose adjustments for PMs and UMs could be considered to ensure drug safety and effectiveness, respectively. Further studies are warranted to confirm other pharmacogenetic associations.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.718281","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T09:23:40Z","timestamp":1633685020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin"],"prefix":"10.3389","volume":"12","author":[{"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mart\u00edn-V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"B1","unstructured":"Duodart\u00ae (dutasteride and tamsulosin 0.5 mg\/0.4 mg) capsules - Drug Label2015"},{"key":"B2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Clin. (Barc)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodological)"},{"key":"B7","unstructured":"Gene [Internet]\n            BethesdaM.\n          2004"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12272-018-1030-6","article-title":"Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes","volume":"41","author":"Byeon","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1177\/0091270011432168","article-title":"Tamsulosin exposure is significantly increased by the CYP2D6*10\/*10 genotype","volume":"52","author":"Choi","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther"},{"key":"B13","unstructured":""},{"key":"B14","unstructured":"Flomax\u00ae (dutasteride and tamsulosin hydrochloride) capsules - Drug Label1997"},{"key":"B15","unstructured":"Jalyn\u00ae (dutasteride and tamsulosin hydrochloride) capsules - Drug Label2010"},{"key":"B16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/bcp.12654","article-title":"Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene","volume":"80","author":"Gotanda","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/ijir.2008.51","article-title":"The role of combination medical therapy in benign prostatic hyperplasia","author":"Greco","year":"2008","journal-title":"Int. J. Impot Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the operational identification of adverse drug reactions","volume":"21","author":"Karch","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00228-018-2501-x","article-title":"Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans","volume":"74","author":"Kim","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cpdd.334","article-title":"Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation","volume":"6","author":"Kurczewski","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management","volume":"206","author":"Lerner","year":"","journal-title":"J. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JU.0000000000002184","article-title":"Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment","volume":"206","author":"Lerner","year":"","journal-title":"J. Urol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.18773\/austprescr.2006.026","article-title":"Meals and medicines","volume":"29","author":"McLachlan","year":"2006","journal-title":"Aust. Prescr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","unstructured":"2018"},{"key":"B25","volume-title":"R: A Language and Environment for Statistical Computing","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics Knowledge for Personalized Medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1748-720x.1991.tb01824.x","article-title":"World Medical Association Declaration of Helsinki","volume":"19","year":"1991","journal-title":"L. Med. Health Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"111087","DOI":"10.1016\/j.biopha.2020.111087","article-title":"Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers","volume":"133","author":"Zubiaur","year":"2021","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.718281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T09:23:43Z","timestamp":1633685023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.718281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":30,"alternative-id":["10.3389\/fphar.2021.718281"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.718281","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"article-number":"718281"}}